Trust Project

The first trials of a vaccine against COVID-19 that bets on a different type of immunity from that of classic vaccines have yielded encouraging results, a study highlighted on Tuesday.

SIGHT: Study concludes that exposure to other coronaviruses protects against COVID-19

The first trials (phase 1) in Germany of a coronavirus vaccine project, called CoVac-1, showed that it stimulated an immunity related to T lymphocytes, according to this study published in the journal Nature.

The T lymphocytes They are a type of white blood cells responsible for the second stage of the immune response, cellular immunity, which completes that of antibodies by directly attacking infected cells and not only against viruses that circulate in the body.

For the first clinical evaluation of this vaccine, 36 people between 18 and 80 years of age participated, who received a single dose of this experimental vaccine.

The CoVac-1 aims to elicit long-lasting immunity against the SARS-CoV2, produced by T lymphocytes, to reproduce as far as possible the immunity acquired through natural infection.

This T cell-induced immunity is a “Important response for the control of viruses and could be used for immunocompromised people”, highlights the Article of Nature.

All participants showed a reaction “Specific” al SARS-CoV2 by T lymphocytes “28 days after the vaccine, a reaction that persisted for at least 3 months”.

This response surpassed that caused by the natural infection of the coronavirus. And it was not “changed” by no current variant (alpha, beta, gamut, and delta).

These results are, however, very embryonic and only larger trials will be able to confirm the real interest of this vaccine to protect against the COVID-19.

A classic vaccine causes the human body to create antibodies after inoculation with a virus. T lymphocytes allow a potentially broader response, although their role in fighting the COVID-19 it is still little known.

But in any case, they can be a decisive help for cancer patients who fail to develop a classical immunity, explains the study.

On the other hand, T cells can facilitate “The production of protective antibodies by B cells”, which are another type of white blood cells, recalls the article by Nature.

According to the criteria of

Know more

RELATED VIDEO

COVID-19: Everything you need to know about vaccinating children under 18 years of age
From this Saturday, October 30 and Sunday, October 31, the vaccination process against COVID-19 will begin for adolescents between 15 and 17 years of age simultaneously throughout the country. The inoculation will be done by age groups to avoid crowds, announced the Minister of Health, Hernando Cevallos. In the following video, know all the details.

IT MAY INTEREST YOU:

Leave a Reply